FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

WealthCom Secures $65M Funding Boost for Expansion

The investment aims to enhance service offerings and accelerate growth.Highlights: WealthCom raises $65 million in Series B funding.New...
FinTech

Financial Health Tools Could Unlock $5B in SME Lending

CFIT report highlights the potential of financial hygiene tools for small businesses.Highlights: CFIT report suggests financial health tools...
FinTech

Coinbase Strengthens UK Crypto Borrowing Options for Customers

Users can now borrow against their cryptocurrency holdings in the UK.Highlights: Coinbase now allows UK customers to borrow...
FinTech

Chase UK Appoints Monzo’s Malani as CEO, Strengthening Leadership Team

Former Monzo executive will lead Chase UK's growth strategy.Highlights: Chase UK appoints Monzo veteran Malani as CEO.This move...